Minireviews
Copyright ©The Author(s) 2024.
World J Exp Med. Jun 20, 2024; 14(2): 92558
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.92558
Figure 2
Figure 2 Eribulin non-mitotic mechanisms of action in cancer. Eribulin induces phenotypic reversal of epithelial to mesenchymal transition, decreases proportions of cancer stem cells, reduces the immunosuppressive tumour microenvironment and promotes vascular remodelling.